Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1475 articles with Gilead Sciences, Inc.
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
NHS England will acquire hepatitis C drugs from the companies at competitive prices and work to identify patients around the country.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (CFO), plans to retire from her role, effective March 1, 2020.
On Wednesday, Kite and Gilead announced the 20-acre facility in Fredericksburg that is expected to employ more than 400 people when it becomes operational.
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis
The U.S. Department of Justice (DOJ) is reviewing a government patent for HIV, according to a retired Centers for Disease Control and Prevention (CDC) scientist.
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes.
Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.
Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis.
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
The companies will collaborate on a clinical trial to combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of NASH.
Data Demonstrate Role of Gilead HCV Medicines in Difficult–to-Treat Patient Populations and in Real-World Settings
Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019
New Proof-of-Concept Data for Combination of Investigational FXR Agonist Cilofexor and ACC Inhibitor Firsocostat in NASH
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of its sales team, according to reports.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of five new global grants programs to continue to support investigator-sponsored research in chronic hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV and HIV co-infection, nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC)
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada® Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.